Category: 171504-98-6

Downstream synthetic route of 171504-98-6

Big data shows that 171504-98-6 is playing an increasingly important role.

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.171504-98-6,Methyl 1,4-Bis(Boc)-2-piperazinecarboxylate,as a common compound, the synthetic route is as follows.

To a solution of Ol ,04-di-tert-butyl (92-methyl piperazine-1 ,2,4-tricarboxylate (3.0 g, 8.71 mmol) in THF (60 mL) at -10 C was added dropwise methyl magnesium bromide 3 M (18.5 mL, 55.5 mmol). The reaction was allowed to warm up slowly to room temperature and stirred overnight. The mixture was quenched by dropwise addition of saturated ammonium chloride solution. The reaction mixture was extracted with EtOAc, dried, and concentrated under vacuum then flash chromatographed over silica (loaded in DCM, eluting with cyclohexane to 30% ethyl acetate in cyclohexane), to afford the intermediate di-tert-butyl 2-(l -hydroxy-l -methyl- ethyl)piperazine-l,4-dicarboxylate (2.5 g, 83% yield). This was then dissolved in DCM (15 mL) and the mixture cooled to -20 C under nitrogen and diethylaminosulfur trifluoride (1.15 mL, 8.71 mmol) was added dropwise. The mixture was stirred at -10 C for 1 hour then gradually allowed to warm to -10 C over 1 hour. Saturated sodium bicarbonate was added dropwise then the mixture was partitioned between saturated sodium bicarbonate solution (20 mL) and DCM (20 mL). The organics were dried, concentrated under reduced pressure and the residue purified by flash chromatography on silica gel (eluting with cyclohexane to 20% ethyl acetate in cyclohexane) to afford the title compound (0.97 g, 38% yield) as a colourless oil. LCMS: RT 5.3 min, MI 347, Method (4LCMS1)., 171504-98-6

Big data shows that 171504-98-6 is playing an increasingly important role.

Reference£º
Patent; CANCER RESEARCH TECHNOLOGY LIMITED; CARSWELL, Emma, L.; CHARLES, Mark, David; COCHI, Anne; DUGAN, Benjamin, J.; EKWURU, Chukuemeka, Tennyson; ELUSTONDO, Fred; FOWLER, Katherine, M.; LEROUX, Frederic, Georges, Marie; MONCK, Nathaniel, J.T.; OTT, Gregory, R.; ROFFEY, Jonathan, R.; SIDHU, Gurwinder; TREMAYNE, Neil; (305 pag.)WO2018/55402; (2018); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics

Downstream synthetic route of 171504-98-6

The synthetic route of 171504-98-6 has been constantly updated, and we look forward to future research findings.

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.171504-98-6,Methyl 1,4-Bis(Boc)-2-piperazinecarboxylate,as a common compound, the synthetic route is as follows.

To a dry flask were added 1, 4-di-tert-butyl 2-methyl piperazine-1, 2, 4-tricarboxylate (10 g, 29.04 mmol) , anhydrous tetrahydrofuran (100 mL) in turn, the mixture was cooled to -78 under N 2, and then LiHDMS (35 mL, 35 mmol, 1 mol/L) was added dropwise slowly. The mixture was keeped at -78 and stirred for 2 hours, then iodomethane (3.7 mL, 59 mmol) was added. The mixture was further stirred for 1 hour, and warmed to rt and stirred for 12 hours. The reaction was quenched with saturated ammonium chloride aqueous solution (50 mL) in an ice bath, and the mixture was extracted with EtOAc (100 mL ¡Á 2) . The combined organic layers were washed with saturated brine (80 mL) , dried over anhydrous sodium sulfate, and concentrated in vacuo, and the residue was purified by silica gel column chromatography (PE/EA (V/V) =10/1) to give the title compound as a colorless oil (8.2 g, 79%) . MS (ESI, pos. ion) m/z: 381.2 [M+Na] +., 171504-98-6

The synthetic route of 171504-98-6 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; SUNSHINE LAKE PHARMA CO., LTD.; LIU, Xinchang; REN, Qingyun; YAN, Guanghua; GOLDMANN, Siegfried; ZHANG, Yingjun; (253 pag.)WO2019/76310; (2019); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics

Brief introduction of 171504-98-6

As the paragraph descriping shows that 171504-98-6 is playing an increasingly important role.

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.171504-98-6,Methyl 1,4-Bis(Boc)-2-piperazinecarboxylate,as a common compound, the synthetic route is as follows.

Step 2: To a solution of Compound All (13.4 g, 38.9 mmol) in 200 mL of anhydrous THF was added freshly prepared LDA (2M in THF, 38 mL) at -78 C. The reaction mixture was stirred for 30 minutes at -78 C. and then warmed to room temperature for 30 minutes. The mixture was cooled down to -78 C. and a solution of allyl bromide (6.7 mL, 77.9 mmol) in 10 mL of THF was added. After the mixture was warmed to room temperature and stirred overnight, the solvent was removed under reduced pressure. The residue was purified by silica gel column chromatography to afford Compound AI (yield 13.6 g, 91%)., 171504-98-6

As the paragraph descriping shows that 171504-98-6 is playing an increasingly important role.

Reference£º
Patent; HOFFMANN-LA ROCHE INC.; Guo, Lei; Hu, Taishan; Kou, Buyu; Lin, Xianfeng; Shen, Hong; Shi, Houguang; Yan, Shixiang; Zhang, Weixing; Zhang, Zhisen; Zhou, Mingwei; Zhu, Wei; US2015/252057; (2015); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics